Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Olympus ( (JP:7733) ) just unveiled an announcement.
Olympus has announced proposed changes to its Board of Directors, adding two seasoned healthcare executives as outside director candidates, subject to shareholder approval at the June 2026 general meeting. The company has nominated Jean-Luc Butel, a veteran leader with extensive international experience at major healthcare multinationals, and Costa Saroukos, a former global chief financial officer at Takeda, while two current directors, including Representative Executive Officer Yasuo Takeuchi, are set to depart.
Olympus expects Butel’s global MedTech expertise and independent perspective to reinforce board governance, improve strategic monitoring, and support sustainable growth in international markets. The appointments are positioned as part of a broader effort to strengthen oversight and enhance medium- to long-term shareholder value, signaling a continued focus on corporate governance and financial discipline at a time of global expansion for the company.
The most recent analyst rating on (JP:7733) stock is a Buy with a Yen1586.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.
More about Olympus
Olympus Corporation is a Japan-based medical technology company listed on the Tokyo Stock Exchange Prime Market, known for its healthcare-focused products and solutions. The group concentrates on the global MedTech sector, where it aims to expand its international footprint and enhance long-term growth and corporate value through strengthened governance and strategic oversight.
Average Trading Volume: 5,388,403
Technical Sentiment Signal: Sell
Current Market Cap: Yen1576.4B
For detailed information about 7733 stock, go to TipRanks’ Stock Analysis page.